LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Risk Variants Identified for Restless Legs Syndrome

By LabMedica International staff writers
Posted on 24 Oct 2017
Print article
Image: The Affymetrix Axiom CEU Genome-Wide Population-Optimized Human Arrays are genotyping panels that offer genetic coverage of rare and common variants for genome-wide disease association studies (Photo courtesy of Thermo Fisher Scientific).
Image: The Affymetrix Axiom CEU Genome-Wide Population-Optimized Human Arrays are genotyping panels that offer genetic coverage of rare and common variants for genome-wide disease association studies (Photo courtesy of Thermo Fisher Scientific).
As many as one in ten people of European ancestry is affected by restless legs syndrome, in which sufferers feel an overwhelming urge to move, often in conjunction with unpleasant sensations, usually in the legs.

Rest and inactivity provoke the symptoms, whereas movement can lead to temporary relief. The condition is chronic and can get progressively worse, with long-lasting effects on patients' mental and physical health. People with restless legs syndrome have substantially impaired sleep, reduced overall quality of life, and increased risk of depression, anxiety disorders, hypertension, and, possibly, cardiovascular disease.

An international team of scientists led by those at German Research Centre for Environmental Health (Neuherberg, Germany) have compared the genetic data from 15,126 patients with 95, 725 controls, and identified a further 13 genetic risk variants. The findings were then replicated in a sample of 31,000 patients and 287,000 controls. The team collected diagnosis data collected from 2003 to 2017, in face-to-face interviews or via questionnaires, and involving cases and controls of European ancestry.

The investigators performed a genome-wide association study (GWAS) and all European samples were genotyped on the Affymetrix Axiom CEU array and UK Samples were genotyped on the Affymetrix UK Biobank Axiom array. They identified common variants by fixed-effect inverse-variance meta-analysis. Significant genome-wide signals were tested for replication in an independent GWAS of 30,770 cases and 286,913 controls, followed by a joint analysis of the discovery and replication stages. They did gene annotation, pathway, and gene-set-enrichment analyses and studied the genetic correlations between restless legs syndrome and traits of interest.

The scientists identified and replicated 13 new risk loci for restless legs syndrome and confirmed the previously identified six risk loci. Meis Homeobox 1 (MEIS1) was confirmed as the strongest genetic risk factor for restless legs syndrome (odds ratio 1.92). Gene prioritization, enrichment, and genetic correlation analyses showed that identified pathways were related to neurodevelopment and highlighted genes linked to axon guidance (associated with SEMA6D), synapse formation (NTNG1), and neuronal specification (HOXB cluster family and MYT1).

Steven Bell, PhD, a genetic epidemiologist and a senior co-author said, “Restless legs syndrome is surprisingly common, but despite this, we know little about what causes it and hence how to treat it. We already know that it has a strong genetic link, and this was something we wanted to explore in more detail.” The study was published on October 10, 2017, in the journal Lancet Neurology.

Related Links:
German Research Centre for Environmental Health

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more